lansoprazole has been researched along with Stevens-Johnson Syndrome in 5 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Stevens-Johnson Syndrome: Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After 2 months of treatment with imatinib 400 mg/day, a 60-year-old white female affected by GIST developed bilateral palpebral edema with hyperemic conjunctivae and labial edema when lansoprazole 15 mg/day was introduced to treat dyspeptic symptomatology." | 7.73 | Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. ( Ardau, R; Chillotti, C; De Lisa, R; Del Zompo, M; Severino, G, 2005) |
| "After 2 months of treatment with imatinib 400 mg/day, a 60-year-old white female affected by GIST developed bilateral palpebral edema with hyperemic conjunctivae and labial edema when lansoprazole 15 mg/day was introduced to treat dyspeptic symptomatology." | 3.73 | Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. ( Ardau, R; Chillotti, C; De Lisa, R; Del Zompo, M; Severino, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, S | 1 |
| Nobeyama, Y | 1 |
| Saeki, H | 1 |
| Asahina, A | 1 |
| Chularojanamontri, L | 1 |
| Jiamton, S | 1 |
| Manapajon, A | 1 |
| Suvanasuthi, S | 1 |
| Kulthanan, K | 1 |
| Dhana, N | 1 |
| Jongjarearnprasert, K | 1 |
| Severino, G | 1 |
| Chillotti, C | 1 |
| De Lisa, R | 1 |
| Del Zompo, M | 1 |
| Ardau, R | 1 |
| Heaton, NR | 1 |
| Edmonds, EV | 1 |
| Francis, ND | 1 |
| Bunker, CB | 1 |
| Bowling, JC | 1 |
| Morar, N | 1 |
| Revuz, J | 1 |
5 other studies available for lansoprazole and Stevens-Johnson Syndrome
| Article | Year |
|---|---|
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2020 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Cas | 2012 |
Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Benzamides; Drug Eruptions; Edema; F | 2005 |
Fatal toxic epidermal necrolysis due to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Drug Eruptions; Erythema Multiform | 2004 |
Fatal toxic epidermal necrolysis due to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Diagnosis, Differential; Drug Eruptions; | 2006 |